Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04990726 · ClinicalTrials.gov registry record
Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors
A clinical trial of Clinical Stage III Cutaneous Melanoma AJCC v8 and Melanoma Stage IV, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- 126
- Enrollment target
- 1
- Study location
NCT04990726 is a study of Clinical Stage III Cutaneous Melanoma AJCC v8 and Melanoma Stage IV that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 126 participants, below the 237-participant average among 23 other Clinical Stage III Cutaneous Melanoma AJCC v8 trials with a reported enrollment target (47% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04990726, a study of Clinical Stage III Cutaneous Melanoma AJCC v8 and Melanoma Stage IV, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 126 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates the immune related toxicity and symptom burden in chronic cancer survivors with melanoma who are receiving adjuvant immunotherapy with immune checkpoint inhibitors. Information collected in this study may help doctors to learn more about the side effects caused by immunotherapy, and to learn if there are any relationships between these side effects and immune and genetic biomarkers found in the blood that may be related to patient's reaction to immunotherapy.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
- BEHAVIORAL Assessment
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2019-12-05 |
| Est. Completion | 2027-02-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04990726
The ClinicalTrials.gov registry entry for NCT04990726 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 237-participant average among 23 other Clinical Stage III Cutaneous Melanoma AJCC v8 trials with a reported enrollment target (47% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Clinical Stage III Cutaneous Melanoma AJCC v8 appearing as the primary indexed condition, and to 4 interventions - of which Biospecimen Collection is the first listed.
NCT04990726 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04990726 about?
NCT04990726 is a clinical study titled "Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors". This study evaluates the immune related toxicity and symptom burden in chronic cancer survivors with melanoma who are receiving adjuvant immunotherapy with immune checkpoint inhibitors. Information collected in this study may help doctors to learn more about the side effects caused by immunotherapy,...
What is the current status of trial NCT04990726?
This trial is currently active not recruiting. The enrollment target is 126 participants. The study started on 2019-12-05. Estimated completion is 2027-02-02.
What conditions does trial NCT04990726 study?
This clinical trial studies the following conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma Stage IV, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8.
What interventions are being tested in trial NCT04990726?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Assessment (BEHAVIORAL).
Who is sponsoring clinical trial NCT04990726?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04990726 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clinical Stage III Cutaneous Melanoma AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
RECRUITING · Phase 1
-
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
RECRUITING · Phase 1
-
Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
RECRUITING
-
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
RECRUITING · Phase 2
-
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
RECRUITING · Phase 1
-
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.